Patient characteristics
| Characteristic . | Total cohort (n = 19) . |
|---|---|
| Demographics | |
| Age in y∗ | 59 (52-61) |
| Male gender | 100% |
| Laboratory features | |
| UBA1 Met41 substitutions | 83% |
| Hemoglobin (g/dL)∗ | 9 (7.8-10.6) |
| MCV (fL)∗ | 100 (92-116) |
| White blood cells (×109/L)∗ | 6.9 (3.4-8.9) |
| Absolute neutrophil counts (×109/L)∗ | 4.4 (2.6-7.8) |
| Absolute monocyte counts (×109/L)∗ | 0.3 (0.1-0.4) |
| Absolute lymphocyte counts (×109/L)∗ | 0.9 (0.4-1.6) |
| Platelet counts (×109/L)∗ | 149 (61-263) |
| MN features | |
| Concomitant MDS | 68% |
| Concomitant MPN | 5% |
| BM blast in MDS (%)∗ | 2 (1-3) |
| IPSS-R MDS (n = 13) categories, (%) | |
| Very low | 15% |
| Low | 31% |
| Intermediate | 38% |
| Missing due to cytogenetic failure | 15% |
| Allo-HCT conditioning | |
| RIC | 74% |
| MAC | 26% |
| Graft source | |
| BM | 5% |
| PBSC | 95% |
| Donor choice | |
| MRD | 16% |
| MUD | 63% |
| MMUD | 5% |
| MMRD | 16% |
| GVHD prophylaxis | |
| Pt-CY | 32% |
| ATG | 58% |
| Alemtuzumab | 10% |
| Characteristic . | Total cohort (n = 19) . |
|---|---|
| Demographics | |
| Age in y∗ | 59 (52-61) |
| Male gender | 100% |
| Laboratory features | |
| UBA1 Met41 substitutions | 83% |
| Hemoglobin (g/dL)∗ | 9 (7.8-10.6) |
| MCV (fL)∗ | 100 (92-116) |
| White blood cells (×109/L)∗ | 6.9 (3.4-8.9) |
| Absolute neutrophil counts (×109/L)∗ | 4.4 (2.6-7.8) |
| Absolute monocyte counts (×109/L)∗ | 0.3 (0.1-0.4) |
| Absolute lymphocyte counts (×109/L)∗ | 0.9 (0.4-1.6) |
| Platelet counts (×109/L)∗ | 149 (61-263) |
| MN features | |
| Concomitant MDS | 68% |
| Concomitant MPN | 5% |
| BM blast in MDS (%)∗ | 2 (1-3) |
| IPSS-R MDS (n = 13) categories, (%) | |
| Very low | 15% |
| Low | 31% |
| Intermediate | 38% |
| Missing due to cytogenetic failure | 15% |
| Allo-HCT conditioning | |
| RIC | 74% |
| MAC | 26% |
| Graft source | |
| BM | 5% |
| PBSC | 95% |
| Donor choice | |
| MRD | 16% |
| MUD | 63% |
| MMUD | 5% |
| MMRD | 16% |
| GVHD prophylaxis | |
| Pt-CY | 32% |
| ATG | 58% |
| Alemtuzumab | 10% |
BM, bone marrow; IPSS-R, Revised International Prognostic Scoring System; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMRD, mismatched related donor, MMUD, mismatched unrelated donor; MN, myeloid neoplasia; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; RIC, reduced-intensity conditioning; PBSC, peripheral blood stem cells.
Data are presented as median (IQR).